Welcome to our dedicated page for ANAPTYSBIO SEC filings (Ticker: ANABV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ANAPTYSBIO's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ANAPTYSBIO's regulatory disclosures and financial reporting.
ANAPTYSBIO director Renton Hollings reported a series of stock option adjustments tied to a corporate separation. On April 20, 2026, he acquired multiple new options to buy AnaptysBio common stock and simultaneously disposed of corresponding older options back to the issuer. The footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into options over both companies’ shares. These are compensation and structural option changes, all held directly, and involve derivatives only rather than open-market trades in common stock.
ANAPTYSBIO director Renton Hollings reported a series of stock option adjustments tied to a corporate separation. On April 20, 2026, he acquired multiple new options to buy AnaptysBio common stock and simultaneously disposed of corresponding older options back to the issuer. The footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was split into options over both companies’ shares. These are compensation and structural option changes, all held directly, and involve derivatives only rather than open-market trades in common stock.
ANAPTYSBIO, INC President and CEO Daniel Faga reported compensation-related stock option changes rather than open-market share trades. On April 20, 2026, he both acquired and disposed of multiple employee stock options covering shares of AnaptysBio common stock.
Footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted so it became an option on both companies’ shares. As a result, Faga acquired new options to buy AnaptysBio common stock at exercise prices such as $10.87, $15.53, $17.02, $22.31, and $32.17 per share, with corresponding dispositions of prior awards back to the issuer.
Several of these options are described as fully vested or vesting 25% on specific January dates with the balance vesting in equal monthly installments over 48 months, contingent on his continued service. The filing reflects grants, adjustments, and issuer-related dispositions of options, not open-market buying or selling of common stock.
ANAPTYSBIO, INC President and CEO Daniel Faga reported compensation-related stock option changes rather than open-market share trades. On April 20, 2026, he both acquired and disposed of multiple employee stock options covering shares of AnaptysBio common stock.
Footnotes explain that, following a pro rata distribution under a Separation and Distribution Agreement between AnaptysBio and First Tracks, each existing option was adjusted so it became an option on both companies’ shares. As a result, Faga acquired new options to buy AnaptysBio common stock at exercise prices such as $10.87, $15.53, $17.02, $22.31, and $32.17 per share, with corresponding dispositions of prior awards back to the issuer.
Several of these options are described as fully vested or vesting 25% on specific January dates with the balance vesting in equal monthly installments over 48 months, contingent on his continued service. The filing reflects grants, adjustments, and issuer-related dispositions of options, not open-market buying or selling of common stock.
AnaptysBio, Inc. completed the spin-off of its former biopharma operations into First Tracks Biotherapeutics, creating a focused royalty management company. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held on the April 6, 2026 record date. First Tracks now trades on Nasdaq under “TRAX,” while AnaptysBio continues under “ANAB.”
Post-spin, AnaptysBio retains the royalty management business, exclusively overseeing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Management highlights a virtual model with limited staff, minimal operating expenses and a targeted greater than 95% EBIT margin. The parties entered into a detailed Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, shared IP, tax matters and up to two years of transition services. The spin-off also triggered board resignations and executive transitions, including the Chief Medical Officer moving to First Tracks and the CEO serving AnaptysBio via a consulting agreement.
AnaptysBio, Inc. completed the spin-off of its former biopharma operations into First Tracks Biotherapeutics, creating a focused royalty management company. Shareholders received one share of First Tracks common stock for every one share of AnaptysBio common stock held on the April 6, 2026 record date. First Tracks now trades on Nasdaq under “TRAX,” while AnaptysBio continues under “ANAB.”
Post-spin, AnaptysBio retains the royalty management business, exclusively overseeing financial collaborations for Jemperli with GSK and imsidolimab with Vanda. Management highlights a virtual model with limited staff, minimal operating expenses and a targeted greater than 95% EBIT margin. The parties entered into a detailed Separation and Distribution Agreement and a Transition Services Agreement governing asset and liability allocations, shared IP, tax matters and up to two years of transition services. The spin-off also triggered board resignations and executive transitions, including the Chief Medical Officer moving to First Tracks and the CEO serving AnaptysBio via a consulting agreement.